Journal of Tuberculosis and Lung Disease ›› 2022, Vol. 3 ›› Issue (6): 517-520.doi: 10.19983/j.issn.2096-8493.20220148
• Review Articles • Previous Articles Next Articles
Chen Qiuqi1, Wu Chaoling2, Zhang Peize3, Deng Guofang3(
)
Received:2022-09-14
Online:2022-12-20
Published:2022-12-15
Contact:
Deng Guofang
E-mail:jxxk1035@yeah.net
Supported by:CLC Number:
Chen Qiuqi, Wu Chaoling, Zhang Peize, Deng Guofang. Current status and prospect of screening and treatment of latent multidrug-resistant tuberculosis infection[J]. Journal of Tuberculosis and Lung Disease , 2022, 3(6): 517-520. doi: 10.19983/j.issn.2096-8493.20220148
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.jtbld.cn/EN/10.19983/j.issn.2096-8493.20220148
| [1] | World Health Organization. Global tuberculosis report 2022. Geneva: World Health Organization, 2022. |
| [2] |
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, 2022, 399(10325):629-655. doi:10.1016/S0140-6736(21)02724-0.
doi: 10.1016/S0140-6736(21)02724-0 URL pmid: 35065702 |
| [3] |
Bruins WS, van Leth F. Effect of secondary preventive therapy on recurrence of tuberculosis in HIV-infected individuals: a systematic review. Infect Dis (Lond), 2017, 49(3):161-169. doi:10.1080/23744235.2016.1262059.
doi: 10.1080/23744235.2016.1262059 URL |
| [4] | World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018. |
| [5] |
Knight GM, McQuaid CF, Dodd PJ, et al. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis, 2019, 19(8): 903-912. doi:10.1016/S1473-3099(19)30307-X.
doi: S1473-3099(19)30307-X URL pmid: 31281059 |
| [6] |
Kendall EA, Fofana MO, Dowdy DW. Burden of transmitted multidrug resistance in epidemics of tuberculosis: a transmission modelling analysis. Lancet Respir Med, 2015, 3(12):963-972. doi:10.1016/S2213-2600(15)00458-0.
doi: 10.1016/S2213-2600(15)00458-0 URL pmid: 26597127 |
| [7] |
Shah NS, Yuen CM, Heo M, et al. Yield of contact investigations in households of patients with drug-resistant tuberculosis: systematic review and meta-analysis. Clin Infect Dis, 2014, 58 (3): 381-391. doi:10.1093/cid/cit643.
doi: 10.1093/cid/cit643 URL pmid: 24065336 |
| [8] |
Dodd PJ, Sismanidis C, Seddon JA. Global burden of drug-resistant tuberculosis in children: a mathematical modelling study. Lancet Infect Dis, 2016, 16(10):1193-1201. doi:10.1016/S1473-3099(16)30132-3.
doi: S1473-3099(16)30132-3 URL pmid: 27342768 |
| [9] |
Jenkins HE, Tolman AW, Yuen CM, et al. Incidence of multidrug-resistant tuberculosis disease in children: systematic review and global estimates. Lancet, 2014, 383(9928):1572-1579. doi:10.1016/S0140-6736(14)60195-1.
doi: 10.1016/S0140-6736(14)60195-1 URL pmid: 24671080 |
| [10] |
Mehra M, Cossrow N, Kambili C, et al. Assessment of tuberculosis burden in China using a dynamic disease simulation model. Int J Tuberc Lung Dis, 2013, 17(9):1186-1194. doi:10.5588/ijtld.12.0959.
doi: 10.5588/ijtld.12.0959 URL pmid: 23827732 |
| [11] | Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. Latent tuberculosis infection: a guide for primary health care providers-Diagnosis of latent TB infection. Atlanta: Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, 2020. |
| [12] | World Health Organization. WHO operational handbook on tuberculosis (Module 1-Prevention): tuberculosis preventive treatment. Geneva: World Health Organization, 2020. |
| [13] |
Li R, Nordio F, Huang CC, et al. Two Clinical Prediction Tools to Improve Tuberculosis Contact Investigation. Clin Infect Dis, 2020, 71(8): e338-e350. doi:10.1093/cid/ciz1221.
doi: 10.1093/cid/ciz1221 URL pmid: 31905406 |
| [14] |
Saunders MJ, Wingfield T, Tovar MA, et al. A score to predict and stratify risk of tuberculosis in adult contacts of tuberculosis index cases: a prospective derivation and external validation cohort study. Lancet Infect Dis, 2017, 17(11):1190-1199. doi:10.1016/S1473-3099(17)30447-4.
doi: S1473-3099(17)30447-4 URL pmid: 28827142 |
| [15] | World Health Organization. Guidelines on the management of latent tuberculosis infection. Geneva: World Health Organization, 2015. |
| [16] |
Marks SM, Mase SR, Morris SB. Systematic Review, Meta-analysis, and Cost-effectiveness of Treatment of Latent Tuberculosis to Reduce Progression to Multidrug-Resistant Tuberculosis. Clin Infect Dis, 2017, 64(12):1670-1677. doi:10.1093/cid/cix208.
doi: 10.1093/cid/cix208 URL pmid: 28329197 |
| [17] |
Gupta A, Swindells S, Kim S, et al. Feasibility of Identifying Household Contacts of Rifampin-and Multidrug-resistant Tuberculosis Cases at High Risk of Progression to Tuberculosis Disease. Clin Infect Dis, 2020, 70(3):425-435. doi:10.1093/cid/ciz235.
doi: 10.1093/cid/ciz235 URL pmid: 30942853 |
| [18] | World Health Organization. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management background document on the 2019 revision. Geneva: World Health Organization, 2019. |
| [19] |
Bamrah S, Brostrom R, Dorina F, et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009—2012. Int J Tuberc Lung Dis, 2014, 18(8): 912-918. doi:10.5588/ijtld.13.0028.
doi: 10.5588/ijtld.13.0028 URL |
| [20] | World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization, 2015. |
| [21] |
Holland DP, Sanders GD, Hamilton CD, et al. Strategies for treating latent multiple-drug resistant tuberculosis: a decision analysis. PLoS One, 2012, 7(1): e30194. doi:10.1371/journal.pone.0030194.
doi: 10.1371/journal.pone.0030194 URL |
| [22] |
Fox GJ, Oxlade O, Menzies D. Fluoroquinolone Therapy for the Prevention of Multidrug-Resistant Tuberculosis in Contacts. A Cost-Effectiveness Analysis. Am J Respir Crit Care Med, 2015, 192(2):229-237. doi:10.1164/rccm.201501-0069OC.
doi: 10.1164/rccm.201501-0069OC URL |
| [23] |
Schluger NW. Prevention of Multidrug-Resistant Tuberculosis in Close Contacts. Back to the Future? Am J Respir Crit Care Med, 2020, 202(8):1077-1078. doi:10.1164/rccm.202006-2488ED.
doi: 10.1164/rccm.202006-2488ED URL |
| [24] |
Migliori GB, Tiberi S, Zumla A, et al. MDR/XDR-TB mana-gement of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network. Int J Infect Dis, 2020, 92S:S15-S25. doi:10.1016/j.ijid.2020.01.042.
doi: 10.1016/j.ijid.2020.01.042 URL |
| [25] |
Nahid P, Mase SR, Migliori GB, et al. Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. Am J Respir Crit Care Med, 2019, 200(10): e93-e142. doi:10.1164/rccm.201909-1874ST.
doi: 10.1164/rccm.201909-1874ST URL |
| [26] |
Seddon JA, Schaaf HS, Marais BJ, et al. Time to act on injectable-free regimens for children with multidrug-resistant tuberculosis. Lancet Respir Med, 2018, 6(9):662-664. doi:10.1016/S2213-2600(18)30329-1.
doi: 10.1016/S2213-2600(18)30329-1 URL pmid: 30191832 |
| [27] |
Gureva T, Turkova A, Yablokova E, et al. Fluoroquinolone preventive therapy for children exposed to MDR-TB. Int J Tuberc Lung Dis, 2022, 26(2):171-173. doi:10.5588/ijtld.21.0443.
doi: 10.5588/ijtld.21.0443 URL pmid: 35086631 |
| [28] |
Huang CC, Becerra MC, Calderon R, et al. Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis. Am J Respir Crit Care Med, 2020, 202(8): 1159-1168. doi:10.1164/rccm.201908-1576OC.
doi: 10.1164/rccm.201908-1576OC URL |
| [29] |
Moore DA. What can we offer to 3 million MDRTB household contacts in 2016?. BMC Med, 2016, 14: 64. doi:10.1186/s12916-016-0610-x.
doi: 10.1186/s12916-016-0610-x URL |
| [30] | 中华人民共和国国家卫生健康委员会办公厅. 结核病预防控制工作技术规范(2020年版). 2020-04-02. |
| [1] | Chen Jing, Qin Yali, Wang Mingdong, Yang Rubin, Wang Qian, Peng Yanqing, Qiu Jiyao, Zhang Xiao, Zhou Xinai. The value of QuantiFERON-TB Gold Plus in the clinical diagnosis of active pulmonary tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 61-67. |
| [2] | Liao Ying, Pang Yan, Zhao Jing, He Gaoqin, You Maolin, Wang Lei. Analysis on the reporting and case finding delay characteristics of pulmonary tuberculosis patients in Liangping District, Chongqing from 2018 to 2023 [J]. Journal of Tuberculosis and Lung Disease, 2025, 6(1): 8-13. |
| [3] | Yunnan Provincial Clinical Medical Center for Infectious Disease, Professional Committee of Respiratory Medicine of Yunnan Hospital Association, Professional Committee of Early Diagnosis and Treatment of Pulmonary Nodules of Kunming Medical Association. Expert consensus on standardized diagnosis and treatment of pulmonary nodules [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(5): 388-397. |
| [4] | Li Xiaoxue, Xiao Xiao, Xu Chunhua, Dong Shulan, Wang Shanshan, Cao Jiayi, Wu Zheyuan, Hu Yi, Shen Xin. The prevalence of latent tuberculosis infection among close contacts of active tuberculosis patients: a Meta-analysis [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(5): 404-414. |
| [5] | Zeng Qin, Zeng Fanqing, He Kun, Yang Honghong, Liu Min. The value of routine pathology microscopy, acid-fast staining, and TB-DNA in diagnosis of lymph node tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(5): 461-467. |
| [6] | Li Yabo, Fan Lijuan, Sun Xiuli, Gou Liangzhi, Ren Beiying, Shi Juanzi, Wang Fang, Ma Xiaoling, Xie Yonghong, Liu Xin, Wu Qianhong. Progress in tuberculosis infection screening, diagnosis and treatment of female infertility patients before in vitro fertilization-embryo transfer [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(4): 352-357. |
| [7] | Yang Hongjie, Qi Fei, Zhang Hongmei, Wu Hongbo, Hu Aimin, Zhang Tongmei. Current status of diagnosis and clinical treatment on co-existent pulmonary tuberculosis and lung cancer [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(3): 273-278. |
| [8] | Sha Min, Zhu Weidong, Jin Yifan, Lyu Leilei, Chen Cheng. Multidimensional differential diagnosis of pulmonary tuberculosis and pulmonary sarcoidosis accompanied by granulomatous inflammation of pulmonary tissue [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(2): 135-142. |
| [9] | National Center of Medical Quality Control for Respiratory Diseases , Tuberculosis Branch of Chinese Medical Association , Tuberculosis Control Branch of Chinese Antituberculosis Association , China⁃Japan Friendship Hospital . Clinical practice guidelines for early detection of pulmonary tuberculosis in general medical facilities [J]. Journal of Tuberculosis and Lung Disease, 2024, 5(1): 1-14. |
| [10] | Luo Chenyang, He Zhiyi. Comorbidities in chronic obstructive pulmonary disease [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(5): 407-412. |
| [11] | Song Yiyan, Ma Liling, Chen Hui, Hang Yin, Chen Sufang, Xu Junchi, Wu Minjuan, Xu Ping. Value of interferon-γ release assays in the diagnosis of tuberculosis [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(4): 313-317. |
| [12] | Jiang Jun, Li Yun, Jiang Wei, Zhang Xiaolong. Analysis of latent tuberculosis infection and related factors in close contacts of pulmonary tuberculosis patients [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(4): 318-322. |
| [13] | Wang Weibing, Li Na, Hao Jing, Jing Rui. An investigation on a cluster of pulmonary tuberculosis in an off-campus study room [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(4): 328-333. |
| [14] | Ge Qiping, Gao Mengqiu. Attach importance to the differential diagnosis of abnormal liver function in tuberculosis patients [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(2): 110-114. |
| [15] | Zhou Jianwei, Zhang Songtao, Li Zhanhui, Xu Xingjun, Zhang Wei, Zhao Hongxia. Baseline screening and follow-up cohort study of close contacts of school tuberculosis epidemic [J]. Journal of Tuberculosis and Lung Disease, 2023, 4(2): 120-127. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
京公安网备11010202008787号
Total visitors: Visitors of today: Now online:
This work is licensed under Creative Commons Attribution 3.0 License.
